Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial
Daniel V.T. Catenacci(University of Chicago), David Cunningham(Royal Marsden NHS Foundation Trust), Agnes Ang(Amgen (United States)), Mohamedtaki Abdulaziz Tejani(AdventHealth Orlando), Sergei Tjulandin, Igor Bondarenko(Dnipro State Medical University), Anghel Adrian Udrea, David H. Ilson(Memorial Sloan Kettering Cancer Center), Cheryl Turkington(Amgen (United Kingdom)), Rui Tang(Jinan University), Evengy Gotovkin(Ivanovo State Medical Academy), Mustapha Tehfé(Centre Hospitalier de l’Université de Montréal), Salah‐Eddin Al‐Batran(Goethe University Frankfurt), Niall C. Tebbutt(Austin Health), Bogusława Karaszewska(State University of Applied Sciences in Konin), Yilong Zhang(Otsuka (Japan)), André M. Murad(Hospital das Clínicas da Universidade Federal de Minas Gerais), Roger Sidhu(Amgen (United States)), Tien Hoang(Amgen (United States)), Ірина Давиденко(Specialized Clinical Psychiatric Hospital No. 1), Ferdinando De Vita(University of Campania "Luigi Vanvitelli")
Cited by 347
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k